This 2022 Recommendation Statement from the US Preventive Services Task Force recommends screening for major depressive disorder (MDD) in adolescents aged 12 to
This 2022 Recommendation Statement from the US Preventive Services Task Force recommends screening for syphilis infection in persons who are at increased risk f
This 2022 Recommendation Statement from the US Preventive Services Task Force concludes that the current evidence is insufficient to assess the balance of benef
NANTES, France (BUSINESS WIRE) Regulatory News:OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces the presentation of two new analyses from the Phase 3 Atalante-1 study of immunotherapy Tedopi®, in patients with advanced non-small cell lung cancer (NSCLC) in secondary resistance after failure of.
This 2022 Recommendation Statement from the US Preventive Services Task Force recommends that for primary prevention of cardiovascular disease (CVD) in adults a